Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18

Veröffentlicht vonadmin

Schwitter, M; Zaman, K; Jerusalem, G; Cazzaniga, M; Greil, R; Ursula, US; Mueller, A; Nussbaum, CU; Auteri, A; Rothgiesser, K; Dietrich, D; Ruhstaller, T

View this publication in the PUBMED database